DNA Methylation — Explain DNA methylation concepts and gene expression effects - Cell Biology

SECTION 1

Historical Context & Motivation

For decades after the elucidation of the DNA double helix, geneticists focused almost exclusively on the nucleotide sequence itself as the carrier of biological information. Yet an uncomfortable puzzle lingered: every somatic cell in a multicellular organism carries the same genome, yet a hepatocyte and a neuron could hardly look or behave more differently. The resolution to this puzzle lies in epigenetics — heritable changes in gene expression that do not involve alterations to the underlying DNA sequence. Among the earliest and best-characterized epigenetic mechanisms is DNA methylation, the covalent addition of a methyl group (−CH₃) to the 5-carbon position of cytosine residues. Understanding how this small chemical modification rewires transcription has been one of the most productive lines of inquiry in modern molecular biology.

1948 • Discovery of 5-Methylcytosine

Rollin Hotchkiss identifies 5-methylcytosine (5mC) in calf thymus DNA using paper chromatography, establishing that modified bases exist naturally in eukaryotic genomes.

1975 • The Riggs–Holliday Hypothesis

Arthur Riggs and Robin Holliday independently propose that DNA methylation patterns could serve as an epigenetic memory system — maintained through cell division — to regulate gene expression and X-chromosome inactivation.

1983 • Methylation Linked to Cancer

Andrew Feinberg and Bert Vogelstein report widespread hypomethylation in colorectal cancer cells compared to normal tissue, launching the field of cancer epigenetics.

1992 • Cloning of DNMT1

Timothy Bestor's laboratory clones DNMT1, the first mammalian DNA methyltransferase gene, confirming the enzymatic basis for maintenance methylation during replication.

2009 • Discovery of TET-Mediated Demethylation

Anjana Rao and colleagues identify TET enzymes that oxidize 5mC to 5-hydroxymethylcytosine (5hmC), revealing an active demethylation pathway and demonstrating that methylation is reversible.

The central question these discoveries converge upon is deceptively simple: how does the addition of a single methyl group — a mere 15 daltons — to a cytosine base alter whether a gene is transcribed or silenced? Answering this requires understanding the chemistry of the modification, the enzymes that write, read, and erase it, and the downstream consequences for chromatin architecture and transcription-factor binding. That is the journey this lesson traces.

SECTION 2

Core Principles of DNA Methylation

Before diving into mechanisms and effects, it is essential to establish the foundational principles that govern DNA methylation in mammalian cells. Although methylation occurs in organisms from bacteria to plants, the discussion here centers on mammalian systems, where the biology is both best characterized and most clinically relevant.

CpG Dinucleotide Specificity

In mammals, DNA methylation occurs almost exclusively at CpG dinucleotides — a cytosine followed by a guanine in the 5′→3′ direction. The 'p' denotes the phosphodiester bond, distinguishing this from a C–G base pair. CpG sites are palindromic: if one strand reads 5′-CG-3′, the complementary strand also reads 5′-CG-3′, enabling symmetrical methylation.

CpG Islands at Gene Promoters

Although CpG dinucleotides are globally under-represented in mammalian genomes (due to spontaneous deamination of 5mC to thymine), clusters of CpGs called CpG islands (≥200 bp, GC content >50%, observed/expected CpG ratio >0.6) are found at roughly 70% of human gene promoters. Most CpG islands are unmethylated in normal cells.

Writers, Readers, and Erasers

Methylation is deposited by DNA methyltransferases (DNMTs), recognized by methyl-CpG-binding domain (MBD) proteins and other readers, and removed through active oxidation by TET dioxygenases followed by base-excision repair. This tripartite system ensures dynamic yet stable regulation.

Maintenance vs. De Novo Methylation

DNMT1 acts as a maintenance methyltransferase, copying methylation patterns from the parental strand to the daughter strand after replication. DNMT3A and DNMT3B function as de novo methyltransferases, establishing new patterns during embryonic development and cellular differentiation.

Methylation Correlates with Silencing

Methylation of CpG islands in gene promoters is strongly associated with transcriptional repression. This can occur directly — by blocking transcription-factor binding — or indirectly — by recruiting repressor complexes that compact chromatin. However, gene-body methylation paradoxically correlates with active transcription.

✦

KEY TAKEAWAY

Think of the genome as a massive reference library. Every cell in the body has the same collection of books (genes), but DNA methylation acts like a librarian's classification system — placing "do not circulate" tags on certain volumes so that only the relevant books are checked out in each cell type. The tags are sticky enough to survive photocopying (replication) because DNMT1 re-applies them to every new copy, yet a specialized team (TET enzymes) can peel them off when the collection policy changes during development.

SECTION 3

Visual Explanation — The Chemistry of 5-Methylcytosine

The diagram below illustrates the core chemical transformation at the heart of DNA methylation: the transfer of a methyl group from the universal methyl donor S-adenosylmethionine (SAM) to the C-5 position of cytosine, catalyzed by a DNA methyltransferase. The resulting product, 5-methylcytosine (5mC), retains normal Watson–Crick base-pairing with guanine but projects its methyl group into the major groove of the DNA double helix, where it can be detected by methyl-binding proteins.

The DNMT enzyme flips the target cytosine out of the DNA helix, forms a covalent intermediate with C-6, and transfers the methyl group from SAM to C-5. The resulting 5-methylcytosine retains standard base-pairing but presents a hydrophobic methyl group in the major groove, altering protein–DNA interactions.

Several features of this reaction deserve emphasis. First, the methyl group is small enough that it does not disrupt the Watson–Crick hydrogen bonds between cytosine and guanine, so the informational content of the DNA sequence is preserved. Second, because CpG dinucleotides are palindromic, both strands of the double helix can carry a methyl mark at the same position, creating a symmetrically methylated CpG site. This symmetry is critical for inheritance: after replication, each daughter duplex retains one methylated (parental) strand, providing a template for DNMT1 to methylate the newly synthesized strand and restore full methylation. Third, the methyl group's position in the major groove — the wider of the two grooves that spiral along the double helix — means it is accessible to proteins that scan the DNA surface, enabling methyl-CpG-binding proteins to distinguish methylated from unmethylated CpGs without unwinding the helix.

SECTION 4

Mechanisms of Methylation-Mediated Gene Silencing

DNA methylation does not simply exist as a passive mark; it actively reshapes the transcriptional landscape through at least two distinct but complementary mechanisms. Understanding these mechanisms is crucial to appreciating why methylation at a promoter almost invariably correlates with gene silencing, whereas methylation within gene bodies does not.

Mechanism 1 — Direct Interference with Transcription-Factor Binding

Many transcription factors recognize short DNA motifs that contain CpG dinucleotides. When the cytosine within such a motif is methylated, the methyl group protrudes into the major groove and sterically or electrostatically prevents the transcription factor from engaging the DNA. This is a direct, cis-acting mechanism: no additional proteins are needed for repression; the methyl mark itself physically blocks activator binding. A well-studied example involves the transcription factor CTCF, an insulator-binding protein whose recognition sequence contains CpGs. Methylation of these CpGs abolishes CTCF binding, thereby disrupting insulator boundaries and altering the three-dimensional organization of chromatin loops.

Mechanism 2 — Recruitment of Methyl-Binding Proteins and Repressor Complexes

The second mechanism is indirect and arguably more potent. A family of proteins containing methyl-CpG-binding domains (MBDs) — including MeCP2, MBD1, MBD2, and MBD4 — selectively binds to methylated CpG sites. These proteins do not act alone: they serve as adaptors that recruit histone deacetylase (HDAC) complexes and chromatin remodelers such as the NuRD complex. HDACs remove acetyl groups from histone tails, promoting chromatin compaction into a heterochromatic state that is physically inaccessible to the transcriptional machinery. The net result is a self-reinforcing silencing loop: DNA methylation recruits histone-modifying enzymes, which compact chromatin, which in turn stabilizes DNA methylation by excluding the transcriptional apparatus.

Left panel: methylation directly blocks transcription-factor binding (e.g., CTCF). Right panel: methyl-CpG-binding domain proteins (MBDs) recruit histone deacetylases and chromatin remodelers, inducing heterochromatin formation. Both pathways converge on transcriptional silencing.

Active Demethylation — The TET Pathway

Methylation is not irreversible. The Ten-eleven translocation (TET) family of dioxygenases (TET1, TET2, TET3) catalyzes the stepwise oxidation of 5-methylcytosine: first to 5-hydroxymethylcytosine (5hmC), then to 5-formylcytosine (5fC), and finally to 5-carboxylcytosine (5caC). These oxidized intermediates are recognized by thymine DNA glycosylase (TDG), which excises them and initiates base-excision repair (BER) to replace them with unmodified cytosine. This TET-TDG-BER pathway enables rapid, locus-specific demethylation — essential during embryonic reprogramming, primordial germ-cell development, and in response to signaling cascades that demand swift transcriptional activation.

SECTION 5

Biological Roles and Genomic Context of DNA Methylation

DNA methylation is not monolithic in its effects; its functional consequences depend critically on genomic context. Methylation at a CpG island promoter silences the downstream gene, yet methylation within the body of an actively transcribed gene correlates with robust expression. The table below organizes the major biological roles of DNA methylation according to the genomic regions where it operates.

Genomic Context	Methylation Status	Biological Effect
CpG island promoters	Unmethylated in most normal cells; methylated in silenced loci	Methylation → transcriptional repression. Aberrant promoter methylation of tumor suppressors drives oncogenesis.
Gene bodies	Heavily methylated in actively transcribed genes	May suppress cryptic intragenic promoters and facilitate efficient elongation by RNA Pol II.
Transposable elements / repeats	Densely methylated genome-wide	Silences LINE, SINE, and other mobile elements, preventing insertional mutagenesis and genomic instability.
Imprinted loci	Parent-of-origin–specific methylation at ICRs	Mono-allelic expression: one parental allele is silenced (e.g., IGF2/H19 locus). Errors cause Prader-Willi, Angelman syndromes.
Inactive X chromosome	Dense methylation of CpG islands	Reinforces X-inactivation initiated by XIST RNA coating; provides stable, long-term silencing for dosage compensation.

Genomic contexts and functional outcomes of DNA methylation

Methylation Dynamics During Development

The methylation landscape undergoes dramatic reprogramming at two key developmental windows. The first occurs shortly after fertilization, when the paternal genome is actively demethylated (via TET3) and the maternal genome is passively demethylated through replication without DNMT1 activity. By the blastocyst stage, the genome is largely hypomethylated. De novo methylation by DNMT3A/3B then re-establishes lineage-specific patterns as cells differentiate. The second wave of reprogramming occurs in primordial germ cells (PGCs), where nearly all methylation — including imprints — is erased and then re-established in a sex-specific manner during gametogenesis. Failure of reprogramming at either window can lead to developmental defects or heritable epigenetic disorders.

ℹ

Clinical Relevance

Aberrant DNA methylation is a hallmark of cancer. Tumor cells typically show global hypomethylation (reactivating transposons, promoting genomic instability) coupled with focal hypermethylation at tumor-suppressor promoters (e.g., RB1, BRCA1, MLH1). This insight has led to FDA-approved hypomethylating agents — azacitidine (Vidaza) and decitabine (Dacogen) — which inhibit DNMTs and are used to treat myelodysplastic syndromes and acute myeloid leukemia.

SECTION 6

Worked Example — Predicting Gene Expression from Methylation Data

Bisulfite sequencing is the gold-standard technique for detecting DNA methylation at single-nucleotide resolution. Sodium bisulfite converts unmethylated cytosines to uracil (read as thymine after PCR), while methylated cytosines are protected and remain as cytosines. By comparing the bisulfite-converted sequence to the reference genome, one can calculate the methylation percentage at each CpG site. The following worked example walks through this analysis.

METHYLATION PERCENTAGE

% Methylation = (C reads / (C reads + T reads)) × 100

At each CpG position in bisulfite-seq data, C reads indicate methylated cytosines (protected from conversion), and T reads indicate unmethylated cytosines (converted to uracil → thymine). A methylation level above ~60% at a CpG island promoter is generally associated with silencing.

Analyzing Bisulfite Sequencing Data at a Tumor-Suppressor Promoter

1
Step 1 — Identify the Genomic Context

You are given bisulfite sequencing data for the CpG island promoter of the CDKN2A (p16) gene — a tumor suppressor — in a colorectal tumor sample and matched normal tissue. The promoter contains 8 CpG sites spanning 350 bp.
2
Step 2 — Tabulate Read Counts for Each CpG Site (Tumor Sample)

At CpG site #4 (representative): 45 sequencing reads show C (methylated) and 5 reads show T (unmethylated), for a total of 50 reads. The remaining 7 CpG sites yield similar patterns with 80–95% methylation.
3
Step 3 — Calculate Methylation Percentage

Applying the formula: % Methylation = (45 / (45 + 5)) × 100 = (45 / 50) × 100 = 90%. This CpG site is heavily methylated in the tumor.

CpG site #4 methylation = 90%
4
Step 4 — Compare to Normal Tissue

In the matched normal tissue, CpG site #4 shows 3 C reads and 47 T reads: % Methylation = (3 / 50) × 100 = 6%. Across all 8 CpG sites, the normal tissue averages 5–8% methylation, consistent with an unmethylated CpG island.

Normal tissue methylation = 6% (unmethylated)
5
Step 5 — Predict Gene Expression Consequence

The CDKN2A promoter is heavily methylated (≈90%) in the tumor but unmethylated (≈6%) in normal tissue. Based on the principle that promoter CpG island methylation correlates with silencing, we predict that CDKN2A is transcriptionally silenced in the tumor. Loss of p16 function removes a critical brake on the cell cycle (p16 inhibits CDK4/6, preventing Rb phosphorylation), thereby promoting uncontrolled proliferation. This finding is consistent with the known role of CDKN2A silencing by methylation in many solid tumors.

Prediction: CDKN2A silenced in tumor → loss of cell-cycle control

SECTION 7

Techniques for Studying DNA Methylation — Strengths and Limitations

A range of experimental techniques has been developed to interrogate DNA methylation, each with distinct trade-offs between resolution, throughput, cost, and the type of information provided. Choosing the appropriate method depends on the biological question being addressed — whether one needs single-base resolution across the entire genome, targeted analysis of specific loci, or a global estimate of methylation levels.

Technique	Strengths	Limitations
Whole-Genome Bisulfite Sequencing (WGBS)	Single-CpG resolution; covers entire genome; quantitative; considered the gold standard	High cost; requires significant sequencing depth (≥30×); cannot distinguish 5mC from 5hmC; bisulfite degrades DNA
Reduced Representation Bisulfite Seq (RRBS)	Enriches for CpG-dense regions (islands); lower cost than WGBS; single-base resolution at targeted sites	Covers only ~10% of CpGs; biased toward CpG islands; misses intergenic and gene-body methylation
Methylation Arrays (e.g., Illumina EPIC)	High throughput; >850,000 CpG sites; cost-effective for large cohorts; well-standardized analysis pipelines	Probe-dependent (cannot detect sites not on the array); limited to pre-selected CpGs; lower resolution than sequencing
Methylated DNA Immunoprecipitation (MeDIP-seq)	Antibody-based enrichment; genome-wide; good for identifying broadly methylated regions	Low resolution (≈150 bp fragments); semi-quantitative; dependent on antibody quality; biased toward CpG-dense regions
Nanopore / PacBio Long-Read Sequencing	Detects 5mC (and 5hmC) directly without bisulfite conversion; preserves long-range haplotype information; detects non-CpG methylation	Higher error rate per read; requires computational base-calling models; currently more expensive for deep whole-genome coverage

Comparison of major DNA methylation profiling techniques

✦

KEY TAKEAWAY

Selecting a methylation assay is analogous to choosing a telescope for astronomy. A wide-field survey telescope (like WGBS) captures the entire sky but is expensive and slow; a targeted telescope (like RRBS) offers exquisite detail in a narrow field of view; and a standardized camera array (like the EPIC chip) efficiently images hundreds of pre-selected regions across many nights (patients). The best instrument depends on whether you need to discover new features or confirm known ones across a large cohort.

SECTION 8

Connections to Advanced Epigenetic Theory

DNA methylation does not operate in isolation. It is deeply intertwined with the broader histone modification landscape and higher-order chromatin organization. Understanding these cross-talk mechanisms is essential for advanced study of epigenetics, as the cell integrates multiple layers of information to determine gene expression states.

Feature	DNA Methylation	Histone Modifications
Chemical substrate	Cytosine in CpG dinucleotides (DNA backbone)	Lysine, arginine, serine residues on histone tails (protein)
Stability	Highly stable; maintained through replication by DNMT1	More dynamic; some marks (e.g., H3K4me3) turn over rapidly
Heritability	Well-established mitotic inheritance; evidence for transgenerational inheritance debated	Mitotic inheritance mechanisms less well defined; Polycomb-mediated memory proposed
Functional output	Promoter methylation → silencing; gene body methylation → elongation support	Combinatorial: H3K4me3 → active promoter; H3K27me3 → repressed; bivalent → poised
Cross-talk	DNMT3A/3B read H3K36me3 via PWWP domain; excludes H3K4me3 regions	UHRF1 reads hemi-methylated CpGs and H3K9me3 simultaneously, coupling both systems

DNA methylation vs. histone modifications: comparative features

The cross-talk between methylation and histone modifications creates a self-reinforcing epigenetic circuit. For example, UHRF1 (ubiquitin-like with PHD and RING finger domains 1) recognizes hemi-methylated DNA at the replication fork and simultaneously reads the repressive histone mark H3K9me2/3. UHRF1 then recruits DNMT1 to restore full methylation and the histone methyltransferase G9a/GLP to maintain H3K9 methylation. This dual recruitment ensures that both epigenetic marks are coordinately inherited. In advanced courses, you will encounter how these feedback loops underpin phenomena such as epigenetic bistability — the ability of a gene to exist in stably 'on' or 'off' states with sharp switching thresholds — and how computational models of these circuits borrow from dynamical systems theory.

💡

Looking Ahead: Epigenetic Editing

CRISPR-based epigenetic editors — such as dCas9 fused to DNMT3A catalytic domains or TET1 catalytic domains — now allow researchers to add or remove methylation at specific loci without altering the DNA sequence. These tools are transforming the field from correlative observation to causal interrogation of methylation's role in gene regulation, development, and disease. Early therapeutic applications targeting aberrant methylation in cancer and neurological disorders are entering preclinical trials.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain why CpG dinucleotides are under-represented in mammalian genomes relative to what would be predicted from the base composition alone. How does this under-representation relate to DNA methylation?

Show answer

5-Methylcytosine is prone to spontaneous hydrolytic deamination, which converts it to thymine rather than to uracil (the deamination product of unmethylated cytosine). Because uracil in DNA is recognized and repaired efficiently by uracil-DNA glycosylase, C→U transitions are corrected. However, 5mC→T transitions produce a normal base (thymine) that is harder for mismatch repair to detect, especially if the mismatch repair system does not operate before the next round of replication. Over evolutionary time, this mutational bias has depleted CpG dinucleotides, resulting in an observed/expected CpG ratio of approximately 0.2 across most of the genome. CpG islands, which are typically unmethylated in the germline, have been protected from this mutational pressure and therefore retain the expected CpG density.

Question 2: BASIC CALCULATION

In a bisulfite sequencing experiment, a specific CpG site in the promoter of gene X shows 72 cytosine reads and 8 thymine reads. Calculate the methylation percentage at this site and predict whether gene X is likely to be transcriptionally active or silent at this locus.

Show answer

Applying the formula: % Methylation = (C reads / (C reads + T reads)) × 100 = (72 / (72 + 8)) × 100 = (72 / 80) × 100 = 90%. A methylation level of 90% at a promoter CpG site strongly suggests that gene X is transcriptionally silenced at this locus. This level of methylation would sterically block transcription-factor binding and/or recruit MBD proteins and HDAC complexes, leading to chromatin compaction. If this pattern is consistent across all CpG sites in the promoter's CpG island, the gene is almost certainly in a repressed state.

Question 3: INTERMEDIATE

DNMT1-knockout mouse embryos die at approximately embryonic day 9.5. However, if you knock out DNMT3A and DNMT3B in adult differentiated cells, the cells initially survive but gradually lose methylation over many cell divisions. Explain the mechanistic basis for this difference, referencing the roles of maintenance versus de novo methylation.

Show answer

DNMT1 is the maintenance methyltransferase that operates at the replication fork, copying methylation patterns from the parental strand to the newly synthesized daughter strand. Its loss causes immediate, genome-wide passive demethylation with each round of replication because hemi-methylated CpG sites are not restored to the fully methylated state. In a rapidly dividing embryo, this leads to catastrophic loss of methylation within a few cell divisions, de-repression of transposable elements, loss of imprinting, and developmental collapse by E9.5. In contrast, DNMT3A and DNMT3B are de novo methyltransferases responsible for establishing new methylation patterns but are not required for copying existing ones. In adult differentiated cells with intact DNMT1, pre-existing methylation marks are faithfully maintained through replication. The gradual loss observed over many divisions likely reflects the stochastic failure of maintenance (DNMT1 fidelity is approximately 95–99% per CpG per division) that would normally be corrected by DNMT3A/3B's de novo activity. Without this 'touch-up' function, methylation slowly erodes.

Question 4: APPLIED

A clinical research team performs EPIC methylation array profiling on tumor biopsies from 200 colorectal cancer patients. They identify a subset of tumors with simultaneous hypermethylation at the promoters of MLH1, CDKN2A, and MGMT — a pattern known as CpG island methylator phenotype (CIMP). Describe the expected functional consequences of silencing each of these three genes and explain why CIMP-positive tumors might respond to treatment with a DNMT inhibitor such as decitabine.

Show answer

MLH1 encodes a mismatch repair protein; its silencing causes microsatellite instability (MSI) because replication errors at microsatellite repeats go uncorrected, contributing to hypermutation and neoantigens. CDKN2A encodes p16/INK4a, a cyclin-dependent kinase inhibitor that restrains the G1→S transition by inhibiting CDK4/6 phosphorylation of Rb; its loss permits uncontrolled cell-cycle entry. MGMT encodes O-6-methylguanine-DNA methyltransferase, a DNA repair enzyme that removes alkyl groups from guanine; its silencing renders cells sensitive to alkylating chemotherapy but also allows accumulation of G→A transition mutations. Treating CIMP-positive tumors with decitabine — a nucleoside analog incorporated into DNA that traps and degrades DNMTs — would globally reduce methylation levels, potentially re-activating these silenced tumor suppressors. Re-expression of MLH1 could restore mismatch repair; re-expression of CDKN2A could reinstate cell-cycle checkpoint control; and re-expression of MGMT could restore DNA repair capacity. However, the non-specificity of DNMT inhibition means that beneficial and detrimental genes may both be de-repressed, underscoring the need for combination approaches and patient stratification.

Question 5: CRITICAL THINKING

A researcher uses dCas9-TET1 to demethylate the promoter of a silenced gene in a fibroblast cell line and observes transient reactivation of transcription that is lost after approximately 10 passages. Propose a mechanistic explanation for this observation and design an experiment to test your hypothesis. Consider the interplay between DNA methylation and histone modifications.

Show answer

The most likely explanation is that while dCas9-TET1 successfully removed DNA methylation from the promoter, the surrounding chromatin retained repressive histone marks — such as H3K9me2/3 or H3K27me3 — that were established by MBD-recruited histone methyltransferases during the original silencing event. These repressive histone marks can recruit de novo DNA methyltransferases (DNMT3A/3B through their ADD/PWWP domains) or maintenance factors (UHRF1 reading H3K9me3), gradually re-establishing promoter methylation over successive passages. Additionally, the transient nature of dCas9-TET1 expression means that once the editor is diluted out, there is no continuous pressure to maintain the demethylated state. To test this hypothesis, one could: (1) perform ChIP-qPCR for H3K9me3 and H3K27me3 at the target promoter immediately after demethylation and at each passage to track whether histone marks persist and correlate with re-methylation; (2) combine dCas9-TET1 with dCas9-p300 (a histone acetyltransferase) or a dCas9-JMJD2A (H3K9 demethylase) to simultaneously remove both layers of repressive marks; (3) use bisulfite pyrosequencing at each passage to confirm the kinetics of re-methylation. If the dual epigenetic editing approach sustains reactivation beyond 10 passages while single-layer editing does not, this would strongly support the model that self-reinforcing cross-talk between DNA methylation and histone modifications drives re-silencing.

SUMMARY

Lesson Summary

Summary

DNA methylation is the covalent addition of a methyl group to the C-5 position of cytosine, occurring predominantly at CpG dinucleotides in mammals. The reaction is catalyzed by DNA methyltransferases (DNMTs): DNMT3A and DNMT3B establish new patterns (de novo methylation), while DNMT1 copies patterns to daughter strands (maintenance methylation). Methylation of CpG island promoters leads to transcriptional silencing through two mechanisms: direct blockade of transcription-factor binding and indirect recruitment of MBD proteins and HDAC complexes that compact chromatin. Active demethylation is achieved by TET dioxygenases through iterative oxidation of 5mC, followed by base-excision repair.

Biologically, DNA methylation plays essential roles in transposon silencing, genomic imprinting, X-chromosome inactivation, and cell-type-specific gene regulation. Aberrant methylation — including global hypomethylation and focal tumor-suppressor hypermethylation — is a hallmark of cancer and the target of FDA-approved DNMT inhibitors. DNA methylation operates in tight cross-talk with histone modifications, forming self-reinforcing epigenetic circuits that ensure stable yet reversible gene expression states across cell generations.